Related Experiment Video
Updated: Nov 29, 2025
Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
Published on: June 26, 2018
CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
Florencia González-Lizárraga1, Diego Ploper1, César L Ávila1
1Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA) (CONICET-UNT-SIPROSA), Pasaje Dorrego 1080, 4000, San Miguel de Tucumán, Argentina.
Chemically modified tetracycline 3 (CMT-3) effectively inhibits alpha-synuclein aggregation, a key driver of Parkinson's disease (PD). This compound also breaks down existing fibrils, offering a potential new therapeutic strategy for PD and similar neurodegenerative disorders.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Parkinson's disease (PD) lacks disease-modifying treatments, relying solely on symptomatic therapies.
- Alpha-synuclein aggregation is a primary pathological hallmark and driver of PD progression.
- Drug repurposing offers a viable strategy to accelerate the development of novel PD therapeutics.
Purpose of the Study:
- To investigate the potential of chemically modified tetracycline 3 (CMT-3) as a disease-modifying agent for Parkinson's disease.
- To evaluate CMT-3's efficacy in inhibiting and disassembling alpha-synuclein aggregation.
Main Methods:
- In vitro studies assessing CMT-3's effect on alpha-synuclein amyloid aggregation.
- Analysis of the toxicity and inflammatory potential of CMT-3-treated species on microglial cells.
- Molecular simulations to model CMT-3 interactions with alpha-synuclein aggregates.
Main Results:
- CMT-3 inhibited alpha-synuclein amyloid formation and generated non-toxic molecular species.
- CMT-3 effectively disassembled preformed alpha-synuclein fibrils.
- Disaggregated species exhibited reduced toxicity and inflammatory responses in microglial cells.
- Molecular simulations elucidated a potential mechanism for fibril disassembly.
Conclusions:
- CMT-3 demonstrates significant potential as a disease-modifying therapeutic for Parkinson's disease.
- CMT-3's ability to inhibit aggregation and disassemble fibrils offers a novel therapeutic approach.
- Further investigation of CMT-3 is warranted for PD and other synucleinopathies.
